

AMENDMENTS TO THE CLAIMS

1. **(Currently amended)** A ~~vaccine~~ composition comprising a polypeptide and ~~a pharmaceutically acceptable vehicle~~, wherein the polypeptide comprises an amino acid sequence that encodes a BAEBL polypeptide or portion thereof.

2. **(Currently amended)** A ~~vaccine~~ composition of Claim 1, wherein the polypeptide portion is an amino acid sequence that encodes a BAEBL region II or portion thereof.

3. **(Currently amended)** A ~~vaccine~~ composition of Claim 2, wherein the polypeptide portion is selected from the group consisting of an amino acid sequence having the following number of consecutive amino acids taken from said BAEBL polypeptide:

6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387,

388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, and 584.

4. **(Currently amended)** A ~~vaccine~~ composition of any of Claims 1-3 wherein said BAEBL polypeptide or portion thereof is defined as having the amino acid sequence of SEQ ID NO: 2 or portion thereof.

5. **(Currently amended)** A ~~vaccine~~ composition of any of Claims 1-3 wherein said BAEBL polypeptide or portion thereof is defined as having at least 70%, 80%, 90%, 95%, or 99% identity to the amino acid sequence of SEQ ID NO: 2 or portion thereof.

6. **(Currently amended)** A ~~vaccine~~ composition of any of Claims 1-3 wherein said BAEBL polypeptide or portion thereof is encoded by a polynucleotide defined as having at least 70%, 80%, 90%, 95%, or 99% identity to the open reading frame of SEQ ID NO: 1 or portion thereof.

7. **(Currently amended)** A ~~vaccine~~ composition of any of Claims 1-3 wherein said BAEBL polypeptide or portion thereof is encoded by a polynucleotide which hybridizes at 42 degree C. in a solution comprising: 50% formamide, 5 times SSC (750 mM NaCl, 75 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5 times Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1 times SSC at about 65 degree C, to a second polynucleotide having the polynucleotide sequence of SEQ ID NO: 1.

8. **(Currently amended)** A ~~vaccine~~ composition of any of Claims 1-3, wherein said BAEBL polypeptide or portion thereof has a polymorphism selected from the group consisting of I at position 185, N at position 239, T at position 261, R at position 261, and E at position 285.

9. **(Currently amended)** A ~~vaccine~~ composition of any of Claims 1-3 further comprising an adjuvant selected from the group consisting of QS-21, Detox-PC, MPL-SE, MoGM-CSF, TiterMax-G, CRL-1005, GERBU, TERamide, PSC97B, Adjumer, PG-026, GSK-1, GcMAF, B-aletine, MPC-026, Adjuvax, CpG ODN, Betafectin, Alum, and MF59.

10. **(Currently amended)** A ~~vaccine~~ composition of any of Claims 1-3 further comprising a second polypeptide, wherein said second polypeptide comprises an amino acid sequence that encodes at least a portion of a Duffy binding protein or erythrocyte binding antigen-175 (EBA-175) of a malaria Plasmodium parasite.

11. **(Currently amended)** A ~~vaccine~~ composition comprising a polynucleotide ~~and a pharmaceutically acceptable vehicle~~, wherein the polynucleotide comprises a nucleic acid sequence that encodes a BAEBL polypeptide or portion thereof.

12. **(Currently amended)** A ~~vaccine~~ composition of Claim 11, wherein the polypeptide portion is an amino acid sequence that encodes a BAEBL region II or portion thereof.

13. **(Currently amended)** A ~~vaccine~~ composition of Claim 12, wherein the polypeptide portion is selected from the group consisting of an amino acid sequence having the following number of consecutive amino acids taken from said BAEBL polypeptide:

6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207,

208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, and 584.

14. **(Currently amended)** A ~~vaccine~~ composition of any of Claims 11-13 wherein said BAEBL polypeptide or portion thereof is defined as having the amino acid sequence of SEQ ID NO: 2 or portion thereof.

15. **(Currently amended)** A ~~vaccine~~ composition of any of Claims 11-13 wherein said BAEBL polypeptide or portion thereof is defined as having at least 70%, 80%, 90%, 95%, or 99% identity to the amino acid sequence of SEQ ID NO: 2 or portion thereof.

16. **(Currently amended)** A ~~vaccine~~ composition of any of Claims 11-13 wherein said BAEBL polypeptide or portion thereof is encoded by a polynucleotide which is identical to the open reading frame of SEQ ID NO: 1 or portion thereof.

17. **(Currently amended)** A ~~vaccine~~ composition of any of Claims 11-13 wherein said BAEBL polypeptide or portion thereof is encoded by a polynucleotide defined as having at least 70%, 80%, 90%, 95%, or 99% identity to the open reading frame of SEQ ID NO: 1 or portion thereof.

18. **(Currently amended)** A ~~vaccine~~ composition of any of Claims 11-13 wherein said BAEBL polypeptide or portion thereof is encoded by a polynucleotide which hybridizes at 42 degree C. in a solution comprising: 50% formamide, 5 times SSC (750 mM NaCl, 75 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5 times Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1 times SSC at about 65 degree C, to a second polynucleotide having the polynucleotide sequence of SEQ ID NO: 1.

19. **(Currently amended)** A ~~vaccine~~ composition of any of Claims 11-13, wherein said BAEBL polypeptide or portion thereof has a polymorphism selected from the group consisting of I at position 185, N at position 239, T at position 261, R at position 261, and E at position 285.

20. **(Original)** A method of vaccinating a human against a malaria Plasmodium parasite comprising the step of administering the vaccine composition of any of claims 1-3 or 11-13 to said human.

21. **(Original)** The method of Claim 20 wherein said step of administration is by protein immunization.

22. **(Original)** The method of Claim 20 wherein said step of administration is by genetic immunization.

23. **(Original)** A method of vaccinating a human against a malaria Plasmodium parasite comprising the step of administering antibodies specific for the binding site of a BAEBL ligand in an amount sufficient to inhibit the ligand from binding red blood cells in the human.